JPMorgan analyst Richard Vosser raised the firm’s price target on GSK to 1,400 GBp from 1,350 GBp and keeps an Underweight rating on the shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- Akebia should update on vadadustat FDA process in next month, says Piper Sandler
- GSK reports Jesduvroq approved by FDA for anemia of CKD in adults on dialysis
- Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
- GSK sees FY23 adjusted EPS up 12%-15%, adjusted operating profit up 10%-12%
- GSK reports Benlysta granted orphan drug designation by FDA